Oxford Drug Design announces further in vivo validation of novel oncology therapeutic mechanism
Oxford Drug Design, the Oxford-based AI drug discovery company, has announced an important milestone in the development of a potential first-in-class cancer […]
IN MEMORIAM: Graham Richards CBE FRS 1939-2025 Founding Chairman, Oxford Drug Design Ltd
With thanks to Dr. Sujuan Ba, President & CEO of the National Foundation or Cancer Research (NFCR) who had provided funding for […]
Oxford Drug Design announces initial in vivo validation of novel oncology therapeutic mechanism
Appoints oncologist Prof. Sarah Blagden to its Scientific Advisory Board. Oxford Drug Design, the Oxford-based AI drug discovery company applying its pioneering […]
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy. The CRUK (Cancer Research UK) Scotland Institute […]